Company Analysis
Sign in

Agios Pharmaceuticals, Inc. (AGIO)

Nasdaq: AGIO · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2008
Full chart Alerts Compare
Grade5.6
◀ Past 5.8● Present 5.9▶ Future 5.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

96 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Agios Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
96
95 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
2
Against 6 in 2024 and 3 in 2023
Applications published
157
10 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals14
Organic fine chemistry7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Agios Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
96 granted
39 published
Agios Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in GB)
0 granted
118 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 30, 202512,428,376Therapeutic compounds and compositionsOrganic fine chemistryAgios Pharmaceuticals, Inc.
Aug 5, 202512,377,093Pyruvate kinase activators for use in therapyOrganic fine chemistryAgios Pharmaceuticals, Inc.
Nov 5, 202412,133,853Pyruvate kinase activators for use in treating blood disordersPharmaceuticalsAgios Pharmaceuticals, Inc.
Apr 16, 202411,957,680Pyruvate kinase activators for use in treating blood disordersPharmaceuticalsAgios Pharmaceuticals, Inc.
Mar 5, 202411,919,915Compounds and methods useful for stabilizing phenylalanine hydroxylase mutationsPharmaceuticalsAgios Pharmaceuticals, Inc.
Jan 23, 202411,878,049Mitapivat therapy and modulators of cytochrome P450PharmaceuticalsAgios Pharmaceuticals, Inc.
Jan 16, 202411,872,225Pyruvate kinase modulators and use thereofPharmaceuticalsAgios Pharmaceuticals, Inc.
Jan 9, 202411,866,411Therapeutic compounds and compositionsOrganic fine chemistryAgios Pharmaceuticals, Inc.
Oct 24, 202311,793,806Pyruvate kinase activators for use in therapyOrganic fine chemistryAgios Pharmaceuticals, Inc.
Jul 18, 2023RE49,582Therapeutic compounds and compositionsAgios Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387386METHODS OF USING PYRUVATE KINASE ACTIVATORSPharmaceuticalsAgios Pharmaceuticals, Inc.
Oct 30, 20252025/0332161PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPYOrganic fine chemistryAgios Pharmaceuticals, Inc.
Oct 16, 20252025/0320201COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSPharmaceuticalsAgios Pharmaceuticals, Inc.
Aug 21, 20252025/0262201COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSPharmaceuticalsAgios Pharmaceuticals, Inc.
May 29, 20252025/0171438COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSPharmaceuticalsAgios Pharmaceuticals, Inc.
May 29, 20252025/0171437(4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIAPharmaceuticalsAgios Pharmaceuticals, Inc.
May 8, 20252025/0144093PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERSPharmaceuticalsAgios Pharmaceuticals, Inc.
Apr 3, 20252025/0108049COMPOUNDS FOR TREATING MDS-ASSOCIATED ANEMIAS AND OTHER CONDITIONSPharmaceuticalsAgios Pharmaceuticals, Inc.
Mar 6, 20252025/0074922COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONSPharmaceuticalsAgios Pharmaceuticals, Inc.
Mar 6, 20252025/0073318MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450PharmaceuticalsAgios Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 11 · Organic fine chemistry 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AGIO · research, not advice